Skip to main content

Table 4 Proposal for reporting of mutational results in GISTs

From: Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors

Information required Optional information
- confirmation of the diagnosis GIST, based on morphological and immunohistochemical findings  
- indicate the type of analysed material (primary tumor, metastasis, local relapse) - indicate date of surgery if appropriate
- in case of a primary GIST indicate the individual risk classification according to consensus classification [27] - according to [5]
- report on molecular findings for every exon analysed; indicate mutations on DNA and protein level in a standardized description according to [30] - indicate homo-/hemizygous mutations
- indicate type of examination method (e.g. PCR and DNA sequencing)
- report on expected response to imatinib treatment based on the individual mutation type, according to recent recommendations;
- KIT exon 9: better response to 800 mg daily
- KIT exon 11: best response (at 400 mg daily)
- PDGFRA exon 18: according to special type of mutation (D842V resistant, deletions mostly responsive)
- report on prognostic relevance of the individual mutation type for clinical behaviour, according to recent data, e.g. [28]
- give an individual suggestion for adjuvant therapy, based on the individual mutation type and according to recent consensus recommendations